Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia

Bioorganic & Medicinal Chemistry
Siyuan XuXiaoming Zha

Abstract

Histone lysine specific demethylase 1 (LSD1) is overexpressed in diverse hematologic disorders and recognized as a promising target for blood medicines. In this study, molecular docking-based virtual screening united with bioevaluation was utilized to identify novel skeleton of 5-arylidene barbiturate as small-molecule inhibitors of LSD1. Among the synthesized derivatives, 12a exhibited reversible and potent inhibition (IC50 = 0.41 μM) and high selectivity over the MAO-A and MAO-B. Notably, 12a strongly induced differentiation effect on acute promyelocytic leukemia NB4 cell line and distinctly escalated the methylation level on histone 3 lysine 4 (H3K4). Our findings indicate that 5-arylidene barbiturate may represent a new skeleton of LSD1 inhibitors and 12a deserve as a promising agent for the further research.

References

Apr 2, 1998·SAR and QSAR in Environmental Research·A J Olson, D S Goodsell
Jun 1, 2006·Proteins·Arun S KonagurthuArthur M Lesk
Nov 28, 2007·Biochemical and Biophysical Research Communications·Shinya MimasuShigeyuki Yokoyama
Mar 18, 2008·Trends in Biochemical Sciences·Federico FornerisAndrea Mattevi
Apr 29, 2009·Journal of Chemical Information and Modeling·Mark D Mackey, James L Melville
Dec 3, 2009·Journal of the American Chemical Society·Rie UedaNaoki Miyata
Mar 25, 2010·International Journal of Cancer. Journal International Du Cancer·Shinya HayamiRyuji Hamamoto
Dec 24, 2011·Acta Biochimica Et Biophysica Sinica·Yunlong HeJing Huang
Apr 14, 2012·Nature Reviews. Drug Discovery·Cheryl H ArrowsmithMatthieu Schapira
Jul 10, 2012·Cell·Mark A Dawson, Tony Kouzarides
Aug 11, 2012·Journal of Medicinal Chemistry·Stuart HazeldinePatrick M Woster
May 21, 2013·Biochimica Et Biophysica Acta·Stefano AmenteBarbara Majello
Oct 25, 2013·Nature·Kristian Helin, Dashyant Dhanak
Jan 1, 2012·Pharmaceuticals·Fernando Lizcano, Jeison Garcia
May 21, 2015·Medicinal Research Reviews·Yi-Chao ZhengHong-Min Liu
Jul 3, 2015·Therapeutic Advances in Hematology·Paolo GallipoliBrian J P Huntly
Feb 18, 2016·Current Topics in Medicinal Chemistry·Yi C ZhengHong M Liu
Mar 18, 2016·ACS Medicinal Chemistry Letters·Vijay Kumar, Gerard Rosse
Mar 29, 2016·Expert Opinion on Therapeutic Patents·Giulia StaziAntonello Mai

❮ Previous
Next ❯

Citations

Sep 6, 2020·Bioorganic Chemistry·Gang JiaZhiyu Song
Dec 8, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Shujing ZhangHongmin Liu
Jan 23, 2021·RSC Medicinal Chemistry·Samir Mehndiratta, Jing-Ping Liou
Feb 24, 2021·Journal of Medicinal Chemistry·Xing-Jie DaiHong-Min Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.